Eva Martinez-Balibrea is a biologist with a strong background in research about cancer. During her career, she has devoted herself to finding the clues for the better clinical management of cancer patients through a translational research perspective. During her Ph.D., she studied how genetic variants predict responses to treatment in colorectal cancer patients. She is still focused on CRC; nowadays, her lines of research are mainly aimed at (i) studying chemokines as prognostic and/or predictive factors; (ii) finding new biomarkers and drug targets through the study of chromatin regulation; and (iii) implementing ex vivo models using organotypic tumor spheroids as a preclinical tool to test immunotherapies and other therapies. However, she has also started a research line in glioblastoma to discover new prognostic genes related to the hypoxia pathway. Importantly, in 2018 she started a research line focusing on glioblastoma tumors. She is Chair of the IMMUNO-model COST Action (CA21135) and the secretary of the EORTC pathobiology group (PBG).